Mucosal melanoma frequently harbors atypical BRAF mutations other than the p.V600 hot spot (such as p.G469A, p.L597Q, p.N581S, p.T599I, and p.G596R), rendering BRAF inhibitors that revolutionized melanoma treatment not applicable in this population [28]. This evidence concerns the gene BRAF and mucositis.